Halligan A, Bonnar J, Sheppard B, Darling M, Walshe J
Rotunda Hospital, Dublin.
Br J Obstet Gynaecol. 1994 Jun;101(6):488-92. doi: 10.1111/j.1471-0528.1994.tb13147.x.
To determine the behaviour of the coagulation variables antithrombin III (ATIII), protein C, thrombin/antithrombin III (TATIII); fibrinolytic activity, tissue plasminogen activator antigen (t-PA), plasminogen activator inhibitors (PAI) 1 and 2, and endothelial involvement by fibronectin assay in normal and pre-eclamptic pregnancies.
Longitudinal and cross-sectional observational study.
Antenatal clinic and maternity hospital.
Thirty-six primigravid normotensive caucasian patients, four of whom subsequently developed pre-eclampsia, and 12 patients with established pre-eclampsia.
Plasma levels of PAI-1, PAI-2 and t-PA antigen were determined using an ELISA technique as were TATIII complex levels of fibronectin. ATIII and protein C plasma levels were assayed using chromogenic substrate techniques.
PAI-1 and PAI-2 antigen levels rose progressively throughout normal pregnancy. Among the established pre-eclamptic group compared with matched normal pregnancies, the PAI-2 antigen level was significantly lower (48.5 +/- 22.8 versus 183.5 +/- 37.4; P < 0.001), the PAI-1 antigen level was significantly higher (122 +/- 34.4 versus 79.2 +/- 19.7; P < 0.001), ATIII activity was significantly lower (87.8 +/- 27.1 versus 110.9 +/- 19.3; P < 0.001) and TATIII complex levels were significantly higher (16.9 +/- 6.4 versus 10.2 +/- 5.9; P < 0.001). Among the four initially normotensive patients who subsequently developed pre-eclampsia, fibronectin levels were significantly elevated from as early as nine weeks of gestation.
Significantly elevated levels of PAI-1 and fibronectin occurring early in pregnancies that subsequently develop pre-eclampsia suggest that these variables may have predictive values. PAI-2 would seem to be a marker of placental function in pre-eclampsia while increased t-PA and TATIII complex levels reflect the severity of the condition.
确定在正常妊娠和子痫前期妊娠中,凝血变量抗凝血酶III(ATIII)、蛋白C、凝血酶/抗凝血酶III(TATIII);纤溶活性、组织纤溶酶原激活物抗原(t-PA)、纤溶酶原激活物抑制剂(PAI)1和2的变化情况,以及通过纤连蛋白测定评估内皮细胞的参与情况。
纵向和横断面观察性研究。
产前诊所和妇产医院。
36例初产妇、血压正常的白种人患者,其中4例随后发生子痫前期,以及12例确诊子痫前期患者。
采用酶联免疫吸附测定(ELISA)技术测定血浆中PAI-1、PAI-2和t-PA抗原水平,以及纤连蛋白的TATIII复合物水平。采用发色底物技术测定ATIII和蛋白C血浆水平。
在正常妊娠期间,PAI-1和PAI-2抗原水平逐渐升高。与匹配的正常妊娠相比,确诊子痫前期组的PAI-2抗原水平显著降低(48.5±22.8对183.5±37.4;P<0.001),PAI-1抗原水平显著升高(122±34.4对79.2±19.7;P<0.001),ATIII活性显著降低(87.8±27.1对110.9±19.3;P<0.001),TATIII复合物水平显著升高(16.9±6.4对~10.2±5.9;P<0.001)。在最初血压正常、随后发生子痫前期的4例患者中,早在妊娠9周时纤连蛋白水平就显著升高。
在随后发生子痫前期的妊娠早期,PAI-1和纤连蛋白水平显著升高,提示这些变量可能具有预测价值。PAI-2似乎是子痫前期胎盘功能的一个标志物而t-PA和TATIII复合物水平升高反映了病情的严重程度。